Tiny drug particles aim to shrink breast tumors
NCT ID NCT07658183
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors or slowing disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL0175 (a nano-medicine that delivers an estrogen receptor down regulator directly into tumor tissue)
- What this could lead to
- If successful, this could identify the best dose of BL0175 to shrink tumors or slow cancer growth in patients with advanced breast cancer.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Action antibody takes aim at advanced breast cancer
- New drug INV-6452 targets Hard-to-Treat breast cancers
- AI phone app aims to ease cancer treatment side effects
- New study aims to sharpen detection of breast cancer metastases
- Engineered immune cells take on Hard-to-Treat breast cancers
- Tattoo marks could help surgeons save more breasts in cancer fight